Nyxoah (NasdaqGM:NYXH) FY Conference Transcript

Summary of Nyxoah's Conference Call Company Overview - Company: Nyxoah - Industry: MedTech, specifically focused on the treatment of obstructive sleep apnea (OSA) through neuromodulation solutions - Market Opportunity: The U.S. OSA market is valued at approximately $10 billion, identified as a blockbuster market with significant under-penetration [2][3] Core Points and Arguments - FDA Approval: Nyxoah has received FDA approval and is actively launching its product in the U.S. market [2] - Technology Differentiation: The Genio system offers a unique bilateral mode of action, which is minimally invasive and does not require an implanted battery, making it distinct from competitors [3][9] - Clinical Evidence: The DREAM study demonstrated a 63.5% reduction in the Apnea-Hypopnea Index (AHI) and a 71.3% oxygen desaturation responder rate, indicating strong efficacy and safety [15][16] - Market Penetration: Nyxoah has implanted over 1,000 patients in Europe and is commercially reimbursed in several countries, including Germany, the U.K., and the UAE [3][19] - U.S. Commercial Strategy: The company focuses on high-volume hypoglossal nerve implanting accounts, which represent about 70% of the total market volume in the U.S. [19][20] - Sales Team: Nyxoah has a dedicated U.S. sales team of approximately 60 people, with 40 focused on high-volume accounts [20] Reimbursement Insights - CPT Codes: Nyxoah has secured CPT codes recognized by both Medicare and private payers, including major insurers like UnitedHealthcare and Blue Cross Blue Shield [22][36] - CMS Communication: Recent updates from CMS indicate that both Genio and its competitors will receive a facility fee of $31,526 for implants, ensuring continued reimbursement [37][40] - Market Dynamics: There is a clear need for dedicated codes for hypoglossal nerve stimulation (HGNS) as the market evolves with multiple technologies [36][37] Competitive Landscape - Demand Drivers: The demand for Genio is driven by physician and patient needs for alternatives to battery-implanted devices, as well as the clinical superiority of the Genio system in treating complex airway obstructions [29][30] - Patient Preferences: Patients prefer the discreet single incision and the absence of a battery replacement requirement, which enhances the appeal of Genio [32] Financial Outlook - Revenue Break-Even: Nyxoah aims to achieve revenue break-even at approximately EUR 150 million, with an expected gross margin of over 80% [42] - Operational Leverage: The company has built out its organization to scale effectively, with limited direct-to-consumer (DTC) spending compared to competitors [43] Additional Insights - Geographic Expansion: Nyxoah is selectively expanding into international markets, with plans to enter Singapore and other Asian markets [24] - Patient Engagement: The Genio system includes a smart wearable component and an app for monitoring sleep data, enhancing patient involvement and data collection for healthcare management [12][13] Conclusion - Nyxoah is positioned as a significant player in the OSA treatment market with a differentiated technology, strong clinical evidence, and a focused commercialization strategy. The company is navigating the complexities of reimbursement while expanding its market presence and enhancing its product offerings [25][36]